- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
TriSalus Life Sciences Inc (TLSI)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.830
5.110
52 wk Range
2.200
7.950
TLSI Income Statement
Featured here, the Income Statement (earnings report) for TriSalus Life Sciences Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
| Period Ending: | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | 8.4 | 12.4 | 18.51 | 29.43 | 45.15 | |||||||||
Total Revenues Growth | aa.aa | +54.6% | +47.58% | +49.31% | +58.99% | +53.41% | |||||||||
Cost Of Revenues | aa.aa | 1.19 | 2.26 | 2.61 | 4.1 | 6.97 | |||||||||
Gross Profit | aa.aa | 7.21 | 10.14 | 15.91 | 25.33 | 38.19 | |||||||||
Gross Profit Growth | aa.aa | +122.74% | +40.68% | +56.86% | +59.24% | +50.77% | |||||||||
Gross Profit Margin % | aa.aa | 85.8% | 81.79% | 85.93% | 86.06% | 84.57% | |||||||||
Other Operating Expenses, Total | aa.aa | 31.24 | 46.58 | 66.08 | 61.49 | 65.13 | |||||||||
| |||||||||||||||
Operating Income | aa.aa | -24.03 | -36.44 | -50.18 | -36.17 | -26.95 | |||||||||
Operating Income Growth | aa.aa | +6.29% | -51.63% | -37.7% | +27.92% | +25.49% | |||||||||
EBIT Margin % | aa.aa | -286.06% | -293.91% | -271.06% | -122.88% | -59.68% | |||||||||
Net Interest Expenses | aa.aa | -1.76 | 0.18 | 0.42 | -2.69 | -4.99 | |||||||||
Net Interest Expenses Growth | aa.aa | +70.83% | +110.16% | +131.84% | -747.23% | -85.74% | |||||||||
Interest Expense, Total | aa.aa | -1.76 | -0 | -0.02 | -3.09 | -5.54 | |||||||||
Interest And Investment Income | aa.aa | - | 0.18 | 0.43 | 0.4 | 0.56 | |||||||||
Other Non Operating Expenses, Total | aa.aa | -0.46 | -10.92 | -17.11 | -2.42 | -4.54 | |||||||||
EBT, Excl. Unusual Items | aa.aa | -26.25 | -47.18 | -66.87 | -41.27 | -36.48 | |||||||||
Gain (Loss) On Sale Of Assets | aa.aa | - | - | - | - | - | |||||||||
Other Unusual Items, Total | aa.aa | -2.59 | - | 11.81 | 11.23 | -2.74 | |||||||||
EBT, Incl. Unusual Items | aa.aa | -28.84 | -47.18 | -59.35 | -30.04 | -39.22 | |||||||||
EBT, Incl. Unusual Items Growth | aa.aa | +9.38% | -63.57% | -25.81% | +49.39% | -30.56% | |||||||||
EBT, Incl. Unusual Items Margin | aa.aa | -343.32% | -380.53% | -320.64% | -102.07% | -86.86% | |||||||||
Income Tax Expense | aa.aa | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |||||||||
Net Income to Company | aa.aa | -28.85 | -47.19 | -59.36 | -30.05 | -39.23 | |||||||||
Minority Interest | aa.aa | - | - | - | - | - | |||||||||
Net Income | aa.aa | -28.85 | -47.19 | -59.36 | -30.05 | -39.23 | |||||||||
Net Income Growth | aa.aa | +9.38% | -63.59% | -25.8% | +49.39% | -30.56% | |||||||||
Net Income Margin % | aa.aa | -343.35% | -380.6% | -320.69% | -102.09% | -86.88% | |||||||||
Preferred Dividend and Other Adjustments | aa.aa | - | 2.83 | 4.24 | 3.19 | 30.46 | |||||||||
Net Income to Common Excl. Extra Items | aa.aa | -28.85 | -50.02 | -63.6 | -33.23 | -69.69 | |||||||||
Basic EPS - Continuing Operations | aa.aa | -3.25 | -161.55 | -6.77 | -1.31 | -1.84 | |||||||||
Basic EPS - Continuing Operations Growth | aa.aa | +21.55% | -4,864.31% | +95.81% | +80.62% | -40.17% | |||||||||
Diluted EPS - Continuing Operations | aa.aa | -3.25 | -161.55 | -6.77 | -1.31 | -1.84 | |||||||||
Diluted EPS - Continuing Operations Growth | aa.aa | +21.55% | -4,864.31% | +95.81% | +80.62% | -40.17% | |||||||||
Basic Weighted Average Shares Outstanding | aa.aa | 8.86 | 0.31 | 9.4 | 25.33 | 37.9 | |||||||||
Diluted Weighted Average Shares Outstanding | aa.aa | 8.86 | 0.31 | 9.4 | 25.33 | 37.9 | |||||||||
Dividend Per Share | aa.aa | - | - | - | - | - | |||||||||
Dividend Per Share Growth | aa.aa | - | - | - | - | - | |||||||||
EBITDA | aa.aa | -23.57 | -36.04 | -49.49 | -35.42 | -26.32 | |||||||||
EBITDA Growth | aa.aa | +6.94% | -52.92% | -37.32% | +28.43% | +25.69% | |||||||||
EBITDA Margin % | aa.aa | -280.54% | -290.7% | -267.36% | -120.35% | -58.29% | |||||||||
EBIT | aa.aa | -24.03 | -36.44 | -50.18 | -36.17 | -26.95 | |||||||||
* In Millions of USD (except for per share items)
FAQ
What was TriSalus Life Sciences’s revenue at year end?
At the end of the last reported fiscal year, TriSalus Life Sciences (TLSI) recorded total revenue of 45.151 million USD.
How much revenue did TriSalus Life Sciences report in the most recent quarter?
In its most recent quarterly earnings report, TriSalus Life Sciences posted revenue of 11.407 million USD.
What was TriSalus Life Sciences’s net income for the year?
For the full year, TriSalus Life Sciences reported net income of -39.227 million USD.
How much net income did TriSalus Life Sciences post in the last quarter?
In the most recent quarter, TriSalus Life Sciences (TLSI) posted net income of -9.187 million USD.
What was TriSalus Life Sciences’s gross profit for the year?
Gross profit for the year was reported at 38.186 million USD.
How much gross profit did TriSalus Life Sciences generate last quarter?
TriSalus Life Sciences recorded gross profit of 9.899 million USD in its latest quarterly report.
What was TriSalus Life Sciences’s annual operating income?
For the full year, TriSalus Life Sciences (TLSI) reported operating income of -26.946 million USD.
What was TriSalus Life Sciences’s operating income last quarter?
Quarterly operating income was -9.813 million USD.
What was TriSalus Life Sciences’s quarterly EBITDA?
In the latest quarter, EBITDA was reported at -9.677 million USD.
What was the quarter-over-quarter change in EBITDA for TriSalus Life Sciences?
EBITDA changed by -16.928% million USD compared to the last quarter.
What is TriSalus Life Sciences’s most recent gross profit margin?
The latest reported gross profit margin for TriSalus Life Sciences (TLSI) is 86.780% million USD.
What is TriSalus Life Sciences’s most recent net income margin?
Net income margin based on recent financials is -80.538% million USD.
What is TriSalus Life Sciences’s most recent EBIT margin?
TriSalus Life Sciences reported an EBIT margin of -86.026% million USD based on current figures.
How did TriSalus Life Sciences’s revenue change compared to the previous quarter?
Revenue changed by 28.183% million USD compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for TriSalus Life Sciences?
In the latest quarter, gross profit changed by 29.078% million USD from the previous quarter.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.